New therapeutic strategies to treat human cancers expressing mutant p53 proteins

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1756-9966

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: New therapeutic strategies to treat human cancers expressing mutant p53 proteins ; volume:37 ; number:1 ; day:15 ; month:2 ; year:2018 ; pages:1-13 ; date:12.2018
Journal of experimental & clinical cancer research ; 37, Heft 1 (15.2.2018), 1-13, 12.2018

Keyword: Krebs
Onkologie

Creator: Blandino, Giovanni

Contributor: Di Agostino, Silvia
SpringerLink (Online service)

DOI: 10.1186/s13046-018-0705-7

URN: urn:nbn:de:1111-201804084905

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:50 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Blandino, Giovanni
Di Agostino, Silvia
SpringerLink (Online service)

Other Objects (12)

p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients

Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246

Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage

APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy

Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers

How mutant p53 empowers Foxh1 fostering leukaemogenesis?

Targeting mutant p53 in cancer: the latest insights

Id4 dependent acetylation restores mutant-p53 transcriptional activity

Exploring mutant p53 targeting strategies for cancer therapy

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation

An in silico approach in predicting the possible mechanism involving restoration of wild-type p53 functions by small molecular weight compounds in tumor cells expressing R273H mutant p53

p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients

Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246

Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage

APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy

Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers

How mutant p53 empowers Foxh1 fostering leukaemogenesis?

Targeting mutant p53 in cancer: the latest insights

Id4 dependent acetylation restores mutant-p53 transcriptional activity

Exploring mutant p53 targeting strategies for cancer therapy

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation

An in silico approach in predicting the possible mechanism involving restoration of wild-type p53 functions by small molecular weight compounds in tumor cells expressing R273H mutant p53

p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients

Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246

Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage

APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy

Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers

How mutant p53 empowers Foxh1 fostering leukaemogenesis?

Targeting mutant p53 in cancer: the latest insights

Id4 dependent acetylation restores mutant-p53 transcriptional activity

Exploring mutant p53 targeting strategies for cancer therapy

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation

An in silico approach in predicting the possible mechanism involving restoration of wild-type p53 functions by small molecular weight compounds in tumor cells expressing R273H mutant p53

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

New therapeutic strategies to treat human cancers expressing mutant p53 proteins

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients

Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246

Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage

APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy

Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers

How mutant p53 empowers Foxh1 fostering leukaemogenesis?

How mutant p53 empowers Foxh1 fostering leukaemogenesis?

Targeting mutant p53 in cancer: the latest insights

Id4 dependent acetylation restores mutant-p53 transcriptional activity

Exploring mutant p53 targeting strategies for cancer therapy

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation

An in silico approach in predicting the possible mechanism involving restoration of wild-type p53 functions by small molecular weight compounds in tumor cells expressing R273H mutant p53

p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients

Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246

Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage

APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy

Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers

How mutant p53 empowers Foxh1 fostering leukaemogenesis?

How mutant p53 empowers Foxh1 fostering leukaemogenesis?

Targeting mutant p53 in cancer: the latest insights

Id4 dependent acetylation restores mutant-p53 transcriptional activity

Exploring mutant p53 targeting strategies for cancer therapy

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation

An in silico approach in predicting the possible mechanism involving restoration of wild-type p53 functions by small molecular weight compounds in tumor cells expressing R273H mutant p53

p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients

Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246

Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage

APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy

Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers

How mutant p53 empowers Foxh1 fostering leukaemogenesis?

How mutant p53 empowers Foxh1 fostering leukaemogenesis?

Targeting mutant p53 in cancer: the latest insights

Id4 dependent acetylation restores mutant-p53 transcriptional activity

Exploring mutant p53 targeting strategies for cancer therapy

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation

An in silico approach in predicting the possible mechanism involving restoration of wild-type p53 functions by small molecular weight compounds in tumor cells expressing R273H mutant p53

Related objects

Reset password